• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.

作者信息

Bhavnani Sujata M, Forrest Alan, Hammel Jeffrey P, Drusano George L, Rubino Christopher M, Ambrose Paul G

机构信息

Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206-1072, USA.

出版信息

Diagn Microbiol Infect Dis. 2008 Sep;62(1):99-101. doi: 10.1016/j.diagmicrobio.2008.04.008. Epub 2008 Jun 25.

DOI:10.1016/j.diagmicrobio.2008.04.008
PMID:18583085
Abstract

Exposure-response analyses were performed using data from 89 patients (10 clinical trials) with Streptococcus pneumoniae community-acquired pneumonia who received quinolones. Relationships between the free-drug AUC/MIC ratio and clinical and microbiologic response were identified. Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials.

摘要

相似文献

1
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Diagn Microbiol Infect Dis. 2008 Sep;62(1):99-101. doi: 10.1016/j.diagmicrobio.2008.04.008. Epub 2008 Jun 25.
2
[New quinolones for the treatment of community-acquired pneumonia--contra].[用于治疗社区获得性肺炎的新型喹诺酮类药物——禁忌]
Dtsch Med Wochenschr. 2003 May 9;128(19):1071. doi: 10.1055/s-2003-39105.
3
[New quinolones for the treatment of community-acquired pneumonia--pro].
Dtsch Med Wochenschr. 2003 May 9;128(19):1070. doi: 10.1055/s-2003-39104.
4
In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.体内真相：全身性肺炎链球菌感染中体外大环内酯类耐药确实会导致临床治疗失败。
Clin Infect Dis. 2002 Sep 1;35(5):565-9. doi: 10.1086/341980. Epub 2002 Aug 9.
5
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.一种描述慢性阻塞性肺疾病急性加重与社区获得性肺炎之间进展的疾病模型：潜在肺部疾病及抗生素药代动力学/药效学的作用
Int J Antimicrob Agents. 2009 Jan;33(1):58-64. doi: 10.1016/j.ijantimicag.2008.07.019. Epub 2008 Oct 1.
6
Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).在社区获得性肺炎（CAP）住院患者的血浆（P）和上皮衬液（ELF）中，使用每日一次500毫克、750毫克和1000毫克的左氧氟沙星对肺炎链球菌进行药效学靶点达成分析。
Int J Antimicrob Agents. 2004 Nov;24(5):479-84. doi: 10.1016/j.ijantimicag.2004.06.010.
7
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.每日两次药代动力学增强型阿莫西林/克拉维酸（2000/125毫克）治疗青霉素耐药肺炎链球菌高流行国家成年社区获得性肺炎患者的疗效与安全性
J Antimicrob Chemother. 2006 Mar;57(3):536-45. doi: 10.1093/jac/dki480. Epub 2006 Jan 30.
8
Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.在青霉素不敏感肺炎链球菌高流行地区用于儿童社区获得性肺炎的抗生素
J Antimicrob Chemother. 2005 Sep;56(3):603-5. doi: 10.1093/jac/dki271. Epub 2005 Jul 22.
9
Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia.当代社区获得性肺炎肺炎链球菌分离株中新型喹诺酮类药物的外排
J Antimicrob Chemother. 2011 Apr;66(4):948-51. doi: 10.1093/jac/dkr004. Epub 2011 Jan 28.
10
[Treatment of community-acquired pneumonia--treatment].[社区获得性肺炎的治疗——治疗]
Ugeskr Laeger. 2008 Jan 14;170(3):127-30.

引用本文的文献

1
Development of a Population Pharmacokinetic Model of Levofloxacin in Healthy Adults and Identification of Optimal Dosing Regimens.健康成年人左氧氟沙星群体药代动力学模型的建立及最佳给药方案的确定。
Pharmaceuticals (Basel). 2025 Apr 25;18(5):621. doi: 10.3390/ph18050621.
2
Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones.成年男性社区获得性肺炎患者的不依从性：阿莫西林与呼吸喹诺酮类药物的相对宽容度
Antibiotics (Basel). 2023 May 1;12(5):838. doi: 10.3390/antibiotics12050838.
3
Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.
泌尿系统感染中氟喹诺酮类药物有效个体化给药的关键因素：个体间药代动力学和药效学变异性
Antibiotics (Basel). 2022 May 11;11(5):641. doi: 10.3390/antibiotics11050641.
4
PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.PK-PD指南针：将感染性疾病药物计量学应用于患者床边
J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):161-177. doi: 10.1007/s10928-017-9518-0. Epub 2017 Mar 28.
5
Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.接受头孢托罗治疗与医院获得性肺炎患者的微生物清除及临床治愈相关。
Antimicrob Agents Chemother. 2014 May;58(5):2512-9. doi: 10.1128/AAC.02611-13. Epub 2014 Feb 10.
6
Guidelines for the management of adult lower respiratory tract infections--full version.成人下呼吸道感染管理指南——全文版。
Clin Microbiol Infect. 2011 Nov;17 Suppl 6(Suppl 6):E1-59. doi: 10.1111/j.1469-0691.2011.03672.x.